United States Patent 5,676,977 Antelman October 14, 1997 Method of curing AIDS with tetrasilver tetroxide molecular crystal devices Abstract The diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag.sub.4 O.sub.4) is utilized for destroying the AIDS virus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans. A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood. The device molecular crystal contains two mono and two trivalent silver ions capable of firing electrons capable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the device electrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger a redox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entities destroying them. The devices are completely non-toxic. However, they put stress on the liver causing hepatomegaly, but there is no loss of liver function. Inventors: Antelman; Marvin S. (Rehovot, IL) Assignee: Antelman Technologies Ltd. (Providence, RI) Family ID: 24643433 Appl. No.: 08/658,955 Filed: May 31, 1996 Related U.S. Patent Documents Application Number Filing Date Patent Number Issue Date 310859 Sep 22, 1994 Current U.S. Class: 424/618 ; 514/495 Current CPC Class: A61K 33/38 (20130101) Current International Class: A61K 33/38 (20060101); A61K 033/38 () Field of Search: ;424/618 ;514/495 References Cited [Referenced By] U.S. Patent Documents 4415565 November 1983 Wysor 4915955 April 1990 Gomori 4952411 August 1990 Fox, Jr. et al. 5073382 December 1991 Antelman 5078902 January 1992 Antelman 5089275 February 1992 Antelman 5211855 May 1993 Antelman 5223149 June 1993 Antelman 5336499 August 1994 Antelman 5571520 November 1996 Antelman Other References Is The AIDS Virus A Science Fiction? by Peter H. Duesberg and Bryan J. Ellison, Policy Review, Summer 1990, pp. 40-51.. Primary Examiner: Hulina; Amy Attorney, Agent or Firm: Salter & Michaelson Parent Case Text This application is a continuation-in-part of patent application Ser. No. 08/310,859 filed Sep. 22, 1994, now abandoned. Claims What is claimed is: 1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject. 2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecular crystals into the bloodstream of the human subject. 3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of said molecular crystals is approximately 40 PPM of the total blood weight of the human subject. Description BACKGROUND OF THE INVENTION The present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularly to the molecular crystal semiconductor tetrasilver tetroxide Ag.sub.4 O.sub.4 which has two monovalent and two trivalent silver ions per molecule, and which through this structural configuration enables intermolecular electron transfer capable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection will completely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices are capable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or not created by the AIDS virus (HIV); so as to restore the immune system. The present invention is based on concepts previously elucidated in applicants U.S. Pat. No. 5,336,499 which discloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totally suppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testing revealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices were harmless when ingested and inhaled, being non-toxic. Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitro against murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensed for these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew University-Hadassah Medical School where said evaluations were done. The initial evaluations entailed experimenting with various silver moieties cited in applicants aforementioned patent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious efforts and initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a single intravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. After success with mice, the inventor was able to test the efficacy of said devices on two select etiological groups of terminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America. The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicator diseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categories with the approximate percent distribution among AIDS patients:
Posted on: Tue, 25 Mar 2014 13:42:53 +0000
Trending Topics
Recently Viewed Topics
© 2015